693 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Glaxo (GSK) Q2 Earnings: Can the Stock Pull a Surprise? http://www.zacks.com/stock/news/224736/glaxo-gsk-q2-earnings-can-the-stock-pull-a-surprise?cid=CS-ZC-FT-224736 Jul 25, 2016 - Glaxo (GSK) is scheduled to report second-quarter 2016 results on Jul 27.
Vertex (VRTX) to Report Q2 Earnings: Is a Surprise in Store? http://www.zacks.com/stock/news/224699/vertex-vrtx-to-report-q2-earnings-is-a-surprise-in-store?cid=CS-ZC-FT-224699 Jul 25, 2016 - Will Orkambi and Kalydeco help Vertex (VRTX) surpass expectations in Q2?
Amgen (AMGN) May Beat Q2 Earnings: Will the Stock Gain? http://www.zacks.com/stock/news/224697/amgen-amgn-may-beat-q2-earnings-will-the-stock-gain?cid=CS-ZC-FT-224697 Jul 25, 2016 - Our proven model shows that Amgen (AMGN) is likely to beat earnings because it has the right combination of two key ingredients.
Pharma Industry Outlook: Fundamentals Remain Strong http://www.zacks.com/commentary/86599/pharma-industry-outlook-fundamentals-remain-strong?cid=CS-ZC--86599 Jul 22, 2016 - Pharma Industry Outlook: Fundamentals Remain Strong
Gilead (GILD) Stock Likely to Beat This Earnings Season http://www.zacks.com/stock/news/224485/gilead-gild-stock-likely-to-beat-this-earnings-season?cid=CS-ZC-FT-224485 Jul 21, 2016 - Gilead Sciences (GILD), which is set to report second-quarter 2016 results on Jul 25, delivered a negative earnings surprise of 1.65% last quarter.
Stock Market News for July 21, 2016 http://www.zacks.com/stock/news/224420/stock-market-news-for-july-21-2016?cid=CS-ZC-FT-224420 Jul 21, 2016 - Sharp growth in Microsoft’s cloud computing business helped both the Dow and the S&P 500 to close at fresh record highs on Wednesday
The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen http://www.zacks.com/stock/news/224406/the-zacks-analyst-blog-highlights-zafgen-celgene-amgen-abbvie-and-biogen?cid=CS-ZC-FT-224406 Jul 21, 2016 - The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen
Eli Lilly (LLY) May Beat Q2 Earnings: Will the Stock Gain? http://www.zacks.com/stock/news/224276/eli-lilly-lly-may-beat-q2-earnings-will-the-stock-gain?cid=CS-ZC-FT-224276 Jul 21, 2016 - The combination of Lilly's Zacks Rank #3 and +1.18% ESP makes us very confident in looking for a positive earnings beat on Jul 26.
Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug http://www.zacks.com/stock/news/224241/biotech-stock-roundup-celgene-in-immuno-oncology-deal-zafgen-drops-lead-drug?cid=CS-ZC-FT-224241 Jul 20, 2016 - While pipeline & regulatory updates will remain in focus, quite a few major biotech companies will be reporting second quarter results over the next few days including Biogen (BIIB).
Valeant's (VRX) Brodalumab BLA Up for Review in the U.S. http://www.zacks.com/stock/news/223881/valeants-vrx-brodalumab-bla-up-for-review-in-the-us?cid=CS-ZC-FT-223881 Jul 18, 2016 - Valeant Pharmaceuticals International, Inc.'s (VRX) Biologic License Application (BLA) for brodalumab is up for review by an FDA panel.

Pages: 1...61626364656667686970

<<<Page 66>